Neuroendocrine Tumors

Quick Answer

Well-differentiated neuroendocrine tumors overexpress somatostatin receptors, so somatostatin-receptor PET (Ga-68/Cu-64-DOTATATE) is the imaging standard for staging, localizing occult primaries, and selecting patients for ¹⁷⁷Lu-DOTATATE peptide-receptor radionuclide therapy (PRRT). Tumor grade (Ki-67 / mitotic rate) and the dual DOTATATE + FDG phenotype guide prognosis and treatment: SSTR-avid, low-FDG disease favors PRRT, while FDG-positive / SSTR-negative disease signals aggressive, dedifferentiated biology.

Definition

Neuroendocrine neoplasms arise from cells of the diffuse neuroendocrine system. They span well-differentiated neuroendocrine tumors (NETs, grades G1–G3) and poorly-differentiated neuroendocrine carcinoma (NEC), and occur most often in the gastroenteropancreatic (GEP) tract and lung. "Functioning" tumors secrete bioactive hormones; "non-functioning" tumors present by mass effect or metastasis.

Synonyms

Carcinoid (older term for well-differentiated NETs, especially lung/GI); islet-cell tumors / pancreatic NET (PanNET); GEP-NET; APUDoma (historical). Functioning subtypes: insulinoma, gastrinoma (Zollinger–Ellison), glucagonoma, VIPoma, somatostatinoma.

Epidemiology

Incidence and prevalence have risen substantially, partly through improved detection. The most common primary sites are the small bowel (midgut), pancreas, and lung. Most disease is sporadic; a minority is syndromic. Many patients present with metastatic (often liver-dominant) disease at diagnosis, yet indolent biology can allow long survival.

Etiology & Risk Factors

• Mostly sporadic.
• Hereditary syndromes: MEN1 (pancreatic NET, pituitary, parathyroid), MEN2 (medullary thyroid cancer + pheochromocytoma), VHL, NF1, and tuberous sclerosis — all can produce NETs/related tumors and warrant a syndromic work-up in young or multifocal cases.

Pathophysiology

The defining imaging/therapeutic feature is somatostatin-receptor subtype 2 (SSTR2) overexpression on well-differentiated cells — the target for DOTATATE imaging, somatostatin-analog therapy, and PRRT. Functioning tumors cause hormone syndromes: carcinoid syndrome (flushing, diarrhea, bronchospasm from serotonin/vasoactive mediators — classically requiring hepatic metastases or retroperitoneal disease to bypass hepatic clearance), insulinoma (hypoglycemia), gastrinoma (refractory ulcers/ZES), glucagonoma, VIPoma (watery diarrhea), and somatostatinoma. Chronic serotonin exposure can cause carcinoid heart disease (right-sided valvular fibrosis). Dedifferentiation lowers SSTR and raises glucose metabolism (FDG avidity).

Genetics & Molecular Biology

• PanNET: MEN1, DAXX/ATRX, and mTOR-pathway alterations (rationale for everolimus).
• Small-bowel NET: relatively quiet genome (frequent chromosome-18 loss).
• Grade is defined by Ki-67 and mitotic count, not by a single mutation, and dominates management.
• SSTR expression (imaging phenotype) generally falls, and glucose metabolism rises, with increasing grade/dedifferentiation.

Histopathology & Grading

Organoid/trabecular architecture with chromogranin A, synaptophysin, and INSM1 positivity. WHO grading of well-differentiated NETs:

The G3 NET vs NEC distinction (both high Ki-67) is crucial: G3 NET is well-differentiated (often still SSTR-avid, PRRT-considerable), whereas NEC is poorly differentiated, SSTR-low/FDG-avid, and treated like small-cell carcinoma.

Clinical Presentation

Non-functioning tumors present with mass effect, bowel obstruction/mesenteric fibrosis (midgut), or incidental/metastatic findings. Functioning tumors present with their hormone syndrome. Carcinoid syndrome implies (usually) hepatic metastatic burden; carcinoid crisis can be precipitated by procedures and is prevented with somatostatin-analog cover.

Laboratory Findings

• Chromogranin A — general NET marker (affected by PPIs, renal function).
• Urinary 5-HIAA — serotonin metabolite for carcinoid syndrome.
• Hormone-specific assays (insulin/C-peptide, gastrin, glucagon, VIP) for functioning tumors; NSE in higher-grade disease.

Imaging Findings by Modality

• SSTR-PET (Ga-68/Cu-64-DOTATATE): the reference for staging, occult-primary localization, and PRRT selection — graded by the Krenning score.
• FDG-PET: complements SSTR imaging in higher-grade disease (FDG-avid, SSTR-low = dedifferentiation).
• CT/MRI: anatomic staging and liver-metastasis characterization (often hypervascular); EUS for small pancreatic primaries.
• In-111-octreotide (legacy SPECT): where PET is unavailable.
• I-123-MIBG: occasionally, in select catecholamine-related or MIBG-avid disease.

Radiopharmaceutical Uptake Mechanisms

DOTATATE (a DOTA-conjugated octreotate) binds SSTR2 and internalizes — the same chelator (DOTA) carries diagnostic Ga-68/Cu-64 or therapeutic Lu-177, the essence of the theranostic pair. Physiologic SSTR uptake occurs in spleen (highest), adrenals, pituitary, kidneys, and the uncinate process of the pancreas (a classic head-of-pancreas mimic). FDG reflects glucose metabolism, rising with grade.

Krenning Score & the Dual-Tracer Phenotype

Scores 3–4 indicate sufficient SSTR expression for PRRT. In higher-grade disease, pair SSTR-PET with FDG-PET: an FDG-positive / SSTR-negative lesion signals dedifferentiation and predicts poorer PRRT response — heterogeneity a single tracer misses.

Typical PET Tracers

Typical SPECT Tracers

• In-111-pentetreotide (OctreoScan) — legacy SSTR SPECT (origin of the Krenning score).
• I-123-MIBG — select NET/paraganglioma settings.

Therapy Indications

• Somatostatin analogs (octreotide LAR, lanreotide): antiproliferative and symptom control (PROMID, CLARINET).
• PRRT (¹⁷⁷Lu-DOTATATE): after SSA progression (NETTER-1) and first-line in grade-2/3 GEP-NET (NETTER-2); approved ≥ 12 y.
• Targeted: everolimus (all GEP-NET; RADIANT) and sunitinib (pancreatic NET).
• Liver-directed: resection, Y-90 radioembolization, TACE, or ablation for liver-dominant disease.
• Chemotherapy: capecitabine/temozolomide (pancreatic NET); platinum-etoposide for NEC.
• Surgery for resectable primaries and, selectively, debulking.

Theranostics

NETs are a foundational theranostic disease: DOTATATE imaging selects (Krenning 3–4) and ¹⁷⁷Lu-DOTATATE treats the same SSTR2 target. Practical points: renal-protective amino-acid co-infusion (kidneys dose-limiting), the dual DOTATATE + FDG work-up in higher grade, and emerging α-labeled (Ac-225-DOTATATE) and retreatment strategies for refractory disease (see the ¹⁷⁷Lu-DOTATATE therapy page).

Differential Diagnosis (of SSTR-avid findings)

• Physiologic splenic, adrenal, pituitary, and uncinate-process uptake; accessory spleen/splenosis mimicking a lesion (heat-damaged RBC scan confirms).
• Inflammation and other SSTR-expressing tissues (granulomas, reactive nodes).
• On the disease side: distinguishing G3 NET from NEC, and functioning-syndrome mimics.

Reporting Checklist

• Report Krenning score for target lesions, the agent, and reference-organ (liver/spleen) uptake for reproducibility.
• Note dual-tracer discordance (FDG-positive/SSTR-negative sites) when a paired FDG study is done.
• Address physiologic/uncinate uptake and accessory-spleen mimics explicitly.
• State PRRT-eligibility implications and liver-tumor burden relevant to liver-directed therapy.

Prognosis

Prognosis is driven by grade (Ki-67), differentiation, stage, and primary site. Well-differentiated G1/G2 disease can be indolent over years; NEC is aggressive with a poor outlook. The dual-tracer phenotype is prognostic — SSTR-avid/FDG-negative disease behaves favorably, FDG-positive disease adversely. Functioning tumors add syndrome-specific morbidity (e.g. carcinoid heart disease).

Board Pearls

Well-differentiated NETs overexpress SSTR2, so DOTATATE PET is the standard for staging, occult-primary localization, and PRRT selection — with Krenning 3–4 (uptake ≥ liver) as the gate. Grade and the dual DOTATATE + FDG phenotype decide therapy: SSTR-avid/FDG-low favors ¹⁷⁷Lu-DOTATATE (NETTER-1/-2), while FDG-positive/SSTR-negative clones flag dedifferentiation, worse prognosis, and poorer PRRT response.

The uncinate process of the pancreas shows physiologic DOTATATE uptake — a classic mimic of a pancreatic-head primary — as do spleen, adrenals, and pituitary; an accessory spleen can masquerade as a lesion.

The G3 NET vs NEC split (both high Ki-67) is decisive: G3 NET is well-differentiated (often SSTR-avid, PRRT-considerable), whereas NEC is poorly differentiated, SSTR-low/FDG-avid, and treated like small-cell carcinoma with platinum-etoposide. This is exactly why higher-grade disease is imaged with both DOTATATE and FDG.

Related Pages

• Tracer: DOTATATE PET agents and FDG; legacy In-111-octreotide.
• Therapy: ¹⁷⁷Lu-DOTATATE (PRRT) and Y-90 radioembolization (liver-dominant disease).
• Related disease: Medullary thyroid carcinoma, adrenal/pheochromocytoma (SSTR overlap); response: theranostics response criteria.

Figure / Diagram Suggestions

• The DOTA theranostic pair cartoon (Ga-68 image → Lu-177 treat, same peptide/chelator).
• A grade → phenotype → therapy flow (Ki-67, SSTR vs FDG, SSA/PRRT/chemo).
• Krenning 0–4 reference plate against liver/spleen.
• A dual-tracer teaching case (SSTR-avid vs FDG-avid discordant lesions).

Common Pitfalls

• A recent long-acting somatostatin-analog injection can competitively block SSTR2 and lower DOTATATE uptake — coordinate scan timing with the SSA cycle so a falsely low Krenning score does not exclude an otherwise PRRT-eligible patient.
• Degenerative/vertebral bone, healing fractures, and inflammatory/reactive nodes can show SSTR uptake and be over-called as metastases without CT correlation.
• Relying on SSTR-PET alone in G2/G3 disease and missing dedifferentiated FDG-positive/SSTR-negative clones — undergrading aggressiveness and overestimating PRRT benefit.
• SUV and Krenning values are not interchangeable across agents (DOTATATE vs DOTATOC vs DOTANOC) or scanners — anchor to reference organs (liver/spleen) and keep the agent constant on serial studies.

Self-Check (Board-Style)